Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

Malmström, Per (creator_code:cre_t): Lund University,Lunds universitet,Medicinska fakulteten,Faculty of Medicine

McGale, P (author)

Wang, Y (author)

Clarke, M (author)

Davies, C (author)

Peto, R (author)

Bijker, N (author)

Solin, L (author)

Darby, S (author)

(creator_code:org_t)

2010-10-18
2010
English.
In: Journal of the National Cancer Institute. Monographs. - : Oxford University Press (OUP). - 1052-6773 .- 1745-6614. ; 2010:41, s. 162-177

Related links:: http://dx.doi.org/10...; show more...; https://academic.oup...; https://lup.lub.lu.s...; https://doi.org/10.1...; https://urn.kb.se/re...; http://kipublication...; show less...

Abstract Subject headings

Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. The proportional reduction in ipsilateral breast events was greater in older than in younger women (2P < .0004 for difference between proportional reductions; 10-year absolute risks: 18.5% vs 29.1% at ages <50 years, 10.8% vs 27.8% at ages ≥ 50 years) but did not differ significantly according to any other available factor. Even for women with negative margins and small low-grade tumors, the absolute reduction in the 10-year risk of ipsilateral breast events was 18.0% (SE 5.5, 12.1% vs 30.1%, 2P = .002). After 10 years of follow-up, there was, however, no significant effect on breast cancer mortality, mortality from causes other than breast cancer, or all-cause mortality.

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

By the author/editor: Malmström, Per; McGale, P; Wang, Y; Clarke, M; Davies, C; Peto, R; show more...; Bijker, N; Solin, L; Darby, S; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

By the university: Lund University; Uppsala University; Karolinska Institutet

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.